Milgamma Protekt (Benfotiamine)

Benfotiamine is a lipophilic prodrug that is converted to thiamine diphosphate, the active cofactor for enzymes involved in carbohydrate metabolism. This enhances transketolase activity, reduces advanced glycation end‑product formation, and supports cellular energy production, especially in nerve and vascular tissues.

The appropriate dose of Milgamma Protekt is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for benfotiamine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Benfotiamine is a fat‑soluble thiamine derivative that achieves higher bioavailability than water‑soluble thiamine salts. This allows more efficient conversion to the active cofactor, potentially offering greater efficacy in supporting nerve health and reducing glycation compared with standard thiamine supplements.

Milgamma Protekt should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency.

Milgamma Protekt is taken orally, as directed by a healthcare professional. The product is typically swallowed with water, and it can be taken with or without food depending on the prescriber’s recommendation.

Serious but rare risks include hypersensitivity reactions such as anaphylaxis, severe skin reactions like Stevens‑Johnson syndrome, and possible hepatic enzyme elevations. Patients should seek immediate medical attention if they experience signs of an allergic reaction or unexplained liver dysfunction.

Individuals with known hypersensitivity to benfotiamine or any excipients in the formulation should avoid using Milgamma Protekt. Additionally, patients with severe renal impairment or those taking medications that may interact should consult their healthcare provider before starting therapy.